Incyte Biosciences International Sàrl
Global biopharmaceutical company focused on discovery and development of therapies in oncology, hematology, dermatology and inflammation/autoimmunity. Activities described on the site include research and development oversight, clinical trial conduct and reporting, medical information and HCP support, patient and disease education, global medical information services, and community and grant programs.
Industries
Nr. of Employees
small (1-50)
Incyte Biosciences International Sàrl
1801 Augustine Cut-off, Wilmington, DE 19803
Products
Jakafi (ruxolitinib)
An oral medication used to treat certain blood cancers by inhibiting Janus kinase enzymes involved in disease progression.
Pemazyre (pemigatinib)
An oral FGFR inhibitor used to treat cholangiocarcinoma with FGFR2 fusions or rearrangements.
Opzelura (ruxolitinib)
A topical formulation of ruxolitinib for treating inflammatory skin conditions such as atopic dermatitis and vitiligo.
IncyteCARES Patient Support Program
A patient assistance program providing support with insurance, financial aid, and access to Incyte medications in the U.S.
MPN Connect
An online resource platform offering educational materials and tools about myeloproliferative neoplasms for healthcare professionals.
FGFRScience
A website educating healthcare professionals about FGFR2 fusions in intrahepatic cholangiocarcinoma and their clinical implications.
Jakafi (ruxolitinib)
An oral medication used to treat certain blood cancers by inhibiting Janus kinase enzymes involved in disease progression.
Pemazyre (pemigatinib)
An oral FGFR inhibitor used to treat cholangiocarcinoma with FGFR2 fusions or rearrangements.
Opzelura (ruxolitinib)
A topical formulation of ruxolitinib for treating inflammatory skin conditions such as atopic dermatitis and vitiligo.
IncyteCARES Patient Support Program
A patient assistance program providing support with insurance, financial aid, and access to Incyte medications in the U.S.
MPN Connect
An online resource platform offering educational materials and tools about myeloproliferative neoplasms for healthcare professionals.
FGFRScience
A website educating healthcare professionals about FGFR2 fusions in intrahepatic cholangiocarcinoma and their clinical implications.
Services
Regional phone and email support plus online medical information portals for healthcare professionals and patients.
Curated libraries with articles, diagnostic tools, videos and podcasts for professional education on specific disease areas.
Point of contact for grant inquiries and support for investigator-initiated studies and collaborations.
Charitable foundation funding, employee volunteering, and matching gift programs focused on oncology patient support and community partnerships.
Regional phone and email support plus online medical information portals for healthcare professionals and patients.
Curated libraries with articles, diagnostic tools, videos and podcasts for professional education on specific disease areas.
Point of contact for grant inquiries and support for investigator-initiated studies and collaborations.
Charitable foundation funding, employee volunteering, and matching gift programs focused on oncology patient support and community partnerships.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Hematology and myeloproliferative neoplasms
- Dermatology development and patient programs
Key Technologies
- Clinical trial design and randomization
- Real-world evidence for site identification
- Digital educational platforms
- AI-assisted patient-facing visualization tools (site referenced)
News & Updates
Company statement lists European Commission approval for a MET-targeted therapy for METex14 skipping advanced non-small cell lung cancer (company statement referenced).
Company statements and pages reference ranking among top biopharma employers by Science Magazine.
Site references inclusion in Newsweek Most Loved Workplaces lists and related workplace recognitions.
Company statement lists European Commission approval for a MET-targeted therapy for METex14 skipping advanced non-small cell lung cancer (company statement referenced).
Company statements and pages reference ranking among top biopharma employers by Science Magazine.
Site references inclusion in Newsweek Most Loved Workplaces lists and related workplace recognitions.